The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.

This pamphlet offers reasons to combine tobacco cessation and substance use disorder treatment, including client testimonials and resources for implementing a tobacco cessation program. It also explains the benefits of offering tobacco cessation programs in substance use disorder treatment settings.

Esta hoja informativa se puede usar como una guía para las personas que buscan tratamiento de salud mental. Ofrece tres pasos necesarios para llevar a cabo antes de utilizar un centro de tratamiento, así como las cinco señales de un centro de tratamiento de calidad, que incluye revisar la acreditación, la medicación, las prácticas basadas en la evidencia, el papel de las familias y las redes de apoyo.

This fact sheet serves as a guide for individuals seeking behavioral health treatment. It provides three necessary steps to complete prior to utilizing a treatment center and the five signs of a quality treatment center, which include a review of the accreditation, medication, evidence-based practices, position on the role of families, and support networks.

This guide offers best practices for treating women living with substance use disorders in co-ed treatment and recovery settings. It highlights the importance of gender differences, cultural sensitivity, and developing healthy relationships.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.

This report presents information about Medicaid coverage of medication-assisted treatment for opioid and alcohol dependence. It covers treatment effectiveness and cost effectiveness. The report also offers examples of innovative approaches in Vermont, Massachusetts, and Maryland.